Tumor Microvessel Density as Marker for Bevacizumab Benefit Tumor Microvessel Density as Marker for Bevacizumab Benefit

What are the potential predictive and prognostic effects of these five biomarkers in patients with ovarian cancer?Journal of the National Cancer Institute
Source: Medscape Today Headlines - Category: Consumer Health News Tags: None Journal Article Source Type: news

Related Links:

In this study, we instituted a talazoparib (PARPi) monotherapy window of opportunity trial to identify informative adaptive responses in high grade serous ovarian cancer patients (HGSOC). Patients were treated for 7 to 14 days with PARPi monotherapy prior to surgery with tissue samples from multiple sites being collected pre- and post-treatment in each patient. Analysis of these samples demonstrated that individual patients displayed different adaptive responses with limited interlesional heterogeneity. Ability of combination therapies designed to interdict adaptive responses to decrease viability was validated using model...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Cosentino F, Turco LC, Fagotti A, Cianci S, Gallotta V, Rosati A, Corbisiero F, Scambia G, Ferrandina G Abstract In 6.2% of gynaecologic malignancies, vascular involvement is reported. Cytoreductive surgery presents in those cases a higher rate of major complications. Arterial-enteric fistula is a very rare post-surgical complication with serious repercussions on the patient's life due to intestinal haemorrhage and the overlapping sepsis. This is the first case report about iliac-colonic fistula formation in recurrent ovarian cancer with lymph-node metastasis after laparoscopic secondary cytoreductive surg...
Source: Journal of Obstetrics and Gynaecology - Category: OBGYN Tags: J Obstet Gynaecol Source Type: research
ConclusionAnatomical varieties of the ureter are of utmost importance for the surgeons, because they increase the possibility of iatrogenic ureteral injury. Ureteral injuries are severe complications of pelvic operations and may increase morbidity and even cause mortality.
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research
ConclusionsOur clinical analyses suggest that in ROC patients with liver disease the assessment of germline and somatic BRCA mutational status can help to select patients elegible for SCS.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
ConclusionsThis was the first study linking RASSF1A hypermethylation variability to PD-L1 expression and clinicopathological characteristics of OC. Epigenetic alteration of RASSF1A was closely associated with nonserous subtype, early stage, and nonrecurrent OC, indicating that RASSF1A hypermethylation may play a role in early detection of OC. Expression of PD-L1 had no relationship with the studied clinicopathological characteristics or RASSF1A hypermethylation in the 112 OC samples.
Source: European Journal of Obstetrics and Gynecology and Reproductive Biology - Category: OBGYN Source Type: research
Authors: Dowdy SC PMID: 31188812 [PubMed - in process]
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research
Title: CA 125 Ovarian Tumor Marker Blood TestCategory: Procedures and TestsCreated: 1/21/1999 12:00:00 AMLast Editorial Review: 6/14/2019 12:00:00 AM
Source: MedicineNet Cancer General - Category: Cancer & Oncology Source Type: news
(West Virginia University) If the American Cancer Society's projections prove accurate, more people will die from pancreatic cancer than from breast, brain, ovarian or prostate cancer this year. WVU researcher Brian Boone was part of a team that studied a new combination of drugs to treat pancreatic cancer. In their meta-analysis, the drug combination -- FOLFIRINOX -- was associated with better surgical options and longer overall survival.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
In many malignancies including ovarian cancer, different angiogenic factors have been related to poor prognosis. However, data on their relations to each other or importance as a prognostic factor in ovarian c...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
CDK12 is a member of the cyclin-dependent kinase family that acts as regulator of DNA damage response gene expression. A c.1047-2A>G splice site variant of the CDK12 gene was recently reported to strongly associate with hereditary breast and ovarian cancer in patients of Tatar ethnic origin. To gain more insight into the potential risk and the population spread of the c.1047-2A>G variant, we have genotyped three breast cancer case-control series of Tatar, Bashkir and Kazakh ethnicity. We identified c.1047-2A>G in 6/155 cases and 12/362 controls of Tatar ancestry, 0/96 cases and 9/189 controls of Bashkir ancestry, ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Health | Ovarian Cancer | Ovaries